Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Bolt Biotherapeutics director Laura Berner received a grant of stock options for 5,000 shares of common stock. The options have an exercise price of $4.43 per share and expire on June 9, 2036.

The award vests on the earlier of June 9, 2027 or the day immediately before the next annual meeting of stockholders, as long as she remains in continuous service until that date. The options will vest in full if there is a change in control of Bolt Biotherapeutics before then. This is an acquisition of derivative securities by grant, not an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Berner Laura

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 5,000 options Exercise price: $4.43 per share Underlying shares: 5,000 shares +3 more

6 metrics

Options granted 5,000 options Stock Option (Right to Buy) grant to director

Exercise price $4.43 per share Stock option strike price

Underlying shares 5,000 shares Common Stock underlying the option

Expiration date June 9, 2036 Option expiration

Total options after grant 5,000 options Total derivative securities following transaction

Vesting latest date June 9, 2027 Latest scheduled vesting date, subject to conditions

Key Terms

Stock Option (Right to Buy), change in control, annual meeting of stockholders, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

change in control financial

"the option will vest in full upon a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders financial

"the day immediately prior to the next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service through such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/11/2026 - 04:15 PM Accepted by SEC EDGAR 06/11/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berner Laura

(Last)

(First)

(Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.43	06/10/2026		A		5,000		⁽¹⁾	06/09/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

	/s/ William P. Quinn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Bolt Biotherapeutics (BOLT) disclose about Laura Berner in this Form 4?

Bolt Biotherapeutics reported that director Laura Berner received a grant of stock options for 5,000 shares of common stock at an exercise price of $4.43 per share, expiring June 9, 2036, subject to specific vesting conditions and potential acceleration on a change in control.

How many Bolt Biotherapeutics (BOLT) options did Laura Berner receive and at what price?

Laura Berner received stock options covering 5,000 shares of Bolt Biotherapeutics common stock. These options have an exercise price of $4.43 per share, meaning she can buy shares at that price once the options vest and before they expire on June 9, 2036.

When do Laura Berner’s Bolt Biotherapeutics (BOLT) stock options vest?

The options vest on the earlier of June 9, 2027 or the day immediately prior to Bolt Biotherapeutics’ next annual meeting of stockholders. Vesting requires her continuous service through that date, with the entire grant vesting earlier if there is a change in control of the company.

What happens to Laura Berner’s BOLT options if there is a change in control?

If there is a change in control of Bolt Biotherapeutics, Laura Berner’s 5,000-share stock option grant will vest in full. This means all granted options become fully exercisable upon such a transaction, even if the original vesting date has not yet been reached.

Is Laura Berner buying or selling Bolt Biotherapeutics (BOLT) shares in this Form 4?

This Form 4 reports an acquisition of stock options, not an open-market stock purchase or sale. Laura Berner was granted options to buy 5,000 shares at $4.43 per share, which she can exercise in the future once they vest and before they expire.

How many Bolt Biotherapeutics (BOLT) options does Laura Berner hold after this transaction?

After this grant, Laura Berner holds 5,000 stock options according to the filing. These options relate to 5,000 underlying shares of Bolt Biotherapeutics common stock and are held directly, subject to the stated vesting schedule and expiration on June 9, 2036.